Neoadjuvant, adjuvant and long-term intravenous/intraperitoneal chemotherapy, hyperthermic intraperitoneal chemotherapy, early postoperative intraperitoneal chemotherapy for ovarian cancer

Authors

  • Evgenia Halkia Third Gynecologic Clinic, University Teaching Hospital Attikon, National and Kapodistrian University of Athens, Medical School, Athens
  • Paul Sugarbaker Center for Gastrointestinal Malignancies, Program in Peritoneal Surface Oncology, MedStar Washington Hospital Center, Washington, DC

DOI:

https://doi.org/10.4081/joper.2017.59

Keywords:

Gynecologic cancer, gynecologic cancer, ovarian cancer, ovarian cancer, hyperthermic intraperitoneal chemotherapy, HIPEC, early postoperative intraperitoneal chemotherapy, EPIC, cytoreductive surgery, IP chemotherapy for ovarian cancer, neoadjuvant chemotherapy, cytoreductive surgery for ovarian cancer, clinical trials, NACT for ovarian cancer.

Abstract

Ovarian cancer is commonly diagnosed after dissemination and is accompanied by a poorer overall prognosis. Treatment incorporates a multimodal approach, utilizing various combinations of surgery and chemotherapy. Ultimately, better screening tests are needed for ovarian cancer to help reduce the burden of advanced-stage disease. For those women with advanced-stage tumors, newer therapeutic strategies may help prolong survival and increase the chance for cure. The aim of this study is to review current trends in the treatment of women diagnosed with advanced-stage epithelial ovarian cancer.

Downloads

Download data is not yet available.

Downloads

Published

2017-07-26

How to Cite

1.
Halkia E, Sugarbaker P. Neoadjuvant, adjuvant and long-term intravenous/intraperitoneal chemotherapy, hyperthermic intraperitoneal chemotherapy, early postoperative intraperitoneal chemotherapy for ovarian cancer. J Peritoneum [Internet]. 2017 Jul. 26 [cited 2024 Dec. 22];2(2). Available from: https://joper.pagepress.net/index.php/joper/article/view/59

Issue

Section

Original Articles from PSOGI Congress